IP Library Granted Patent US 10,059,709
Granted Patent B2
US 10,059,709 · App. 15/119,800 · Granted Aug 28, 2018

Compounds

Inventors: Noelle Gauvry (Kembs, FR); Chouaib Tahtaoui (Rixheim, FR); Pascal Furet (Thann, FR); Pierre Ducray (Village-Neuf, FR)
Assignee: Elanco Tiergesundheit AG
C07D471/14C07D239/42C07D239/46C07D239/48C07D471/04C07D473/34C07D487/04C07D495/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,059,709
App. No.
15/119,800
Granted
Aug 28, 2018
Kind
B2
Abstract

The invention relates to a compound of formula (I) wherein the variables have the meaning as indicated in the claims; in free form and in salt form; and optionally the enantiomers and geometrical isomers thereof. The compounds of formula (I) are useful as therapeutic agent for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, inflammatory bowel diseases, Crohn's disease, Alzheimer's disease, leukemia, osteoarthritis, control of pruritus, chronic respiratory disease or keratoconjunctivitis in mammals.

Claims (9)

1. A compound of formula

wherein R is C 1 -C 4 -alkyl or C 3 -C 5 -cycloalkyl; and A is

a radical of formula

wherein Y is NH, N(C 1 -C 2 -alkyl) or O, R 2 is cyano (CN), nitro (NO 2 ), C(O)NR′R″, C(O)OR′ or NR′R″, and R′ and R″ are each independently of the other H or C 1 -C 4 -alkyl,

or a veterinary acceptable salt thereof.

2. The compound of claim 1 or a veterinary acceptable salt thereof, wherein R 2 is cyano or nitro and Y is NH, N(CH 3 ) or O.

3. A pharmaceutical composition comprising a compound according to claim 1 or a veterinary acceptable salt thereof, and a pharmaceutical acceptable carrier.

4. A method of treating atopic dermatitis, eczema, psoriasis, scleroderma, pruritus and other pruritic conditions, or allergic dermatitis, the method comprising administering to a mammal in need thereof an effective amount of a compound according to claim 1 or a veterinary acceptable salt thereof.

5. The method according to claim 4 , wherein the mammal is a dog.

Assignments (5)
CHANGE OF NAME Recorded Aug 23, 2017
From: NOVARTIS TIERGESUNDHEIT AG
To: ELANCO TIERGESUNDHEIT AG
Reel/Frame 043363/0007 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 19, 2016
From: FURET, PASCAL
To: NOVARTIS PHARMA AG
Reel/Frame 039480/0132 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 19, 2016
From: NOVARTIS ANIMAL HEALTH, INC.; NOVARTIS PHARMA AG
To: NOVARTIS AG
Reel/Frame 039480/0172 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 19, 2016
From: DUCRAY, PIERRE; GAUVRY, NOELLE; TAHTAOUI, CHOUAIB
To: NOVARATIS ANIMAL HEALTH, INC.
Reel/Frame 039753/0029 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 19, 2016
From: NOVARTIS AG
To: NOVARTIS TIERGESUNDHEIT AG
Reel/Frame 039753/0714 →
Priority Claims (1)
EP 14162391 · Mar 28, 2014 · regional
Continuity (1)
Related Publication 20170050965A1 · Feb 23, 2017